PTP4A3 and neoplasm: This is therefore a timely utility for PRL3-zumab in blocking PGCCs-driven tumor recurrence by targeted inhibition of PRL3 for the urgent use in inhibiting tumor growth and more importantly, to reduce cancer metastasis and tumor relapse.